Lee’s Pharmaceutical Holdings Limited Product Pipeline Review to 2012
Upcoming SlideShare
Loading in...5
×

Like this? Share it with your network

Share

Lee’s Pharmaceutical Holdings Limited Product Pipeline Review to 2012

  • 305 views
Uploaded on

RnR Market Research pharmaceuticals report, “Lee’s Pharmaceutical Holdings Limited – Product Pipeline Review – 2012″ provides data on the Lee’s Pharmaceutical Holdings Limited’s research and......

RnR Market Research pharmaceuticals report, “Lee’s Pharmaceutical Holdings Limited – Product Pipeline Review – 2012″ provides data on the Lee’s Pharmaceutical Holdings Limited’s research and development focus. The report includes information on current developmental pipeline.

More in: Technology
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
305
On Slideshare
305
From Embeds
0
Number of Embeds
0

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. RnR Market Research Offers “Lee’s Pharmaceutical Holdings Limited – Product PipelineReview – 2012” Report at US$ 1500 (Single User License). The report got published in Nov2012 & contains 80 pages.Lee’s Pharmaceutical Holdings Limited – Product Pipeline Review – 2012SummaryRnR Market Research pharmaceuticals report, “Lee’s Pharmaceutical Holdings Limited – Product PipelineReview – 2012″ provides data on the Lee’s Pharmaceutical Holdings Limited’s research and developmentfocus. The report includes information on current developmental pipeline, complete with latest updates, andfeatures on discontinued and dormant projects.This report is built using data and information sourced from RnR Market Research proprietary databases,Lee’s Pharmaceutical Holdings Limited’s corporate website, SEC filings, investor presentations and featuredpress releases, both from Lee’s Pharmaceutical Holdings Limited and industry-specific third party sources,put together by RnR Market Research team.Scope  Lee’s Pharmaceutical Holdings Limited – Brief Lee’s Pharmaceutical Holdings Limited overview including business description, key information and facts, and its locations and subsidiaries.  Review of current pipeline of Lee’s Pharmaceutical Holdings Limited human therapeutic division.  Overview of pipeline therapeutics across various therapy areas.  Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.  Product profiles for late stage and clinical stage products of Lee’s Pharmaceutical Holdings Limited with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.  Recent updates of the Lee’s Pharmaceutical Holdings Limited’s pipeline in the last quarter.  Key discontinued and dormant projects.  Latest news and deals relating to the products.Get your report copy of this report @ http://www.rnrmarketresearch.com/the-chinese-rd-landscape-chemical-engineering-2-market-report.htmlReasons to buy  Evaluate Lee’s Pharmaceutical Holdings Limited’s strategic position with total access to detailed information on its product pipeline.  Assess the growth potential of Lee’s Pharmaceutical Holdings Limited in its therapy areas of focus.  Identify new drug targets and therapeutic classes in the Lee’s Pharmaceutical Holdings Limited’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.  Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.  Exploit collaboration and partnership opportunities with Lee’s Pharmaceutical Holdings Limited.
  • 2.  Avoid Intellectual Property Rights related issues.  Explore the dormant and discontinued projects of Lee’s Pharmaceutical Holdings Limited and identify potential opportunities in those areas.Table Of contentsTable of Contents 2List of Tables 6List of Figures 6Lees Pharmaceutical Holdings Limited Snapshot 7Lees Pharmaceutical Holdings Limited Overview 7Key Information 7Key Facts 7Lees Pharmaceutical Holdings Limited - Research and Development Overview 8Key Therapeutic Areas 8Lees Pharmaceutical Holdings Limited - Pipeline Review 12Pipeline Products by Stage of Development 12Pipeline Products - Monotherapy 13Lees Pharmaceutical Holdings Limited - Pipeline Products Glance 14Lees Pharmaceutical Holdings Limited - Late Stage Pipeline 14Registration Filed Products/Combination Treatment Modalities 14Phase III Products/Combination Treatment Modalities 15Lees Pharmaceutical Holdings Limited Clinical Stage Pipeline Products 16Phase II Products/Combination Treatment Modalities 16Phase I Products/Combination Treatment Modalities 17Lees Pharmaceutical Holdings Limited - Early Stage Pipeline Products 18Pre-Clinical Products/Combination Treatment Modalities 18Lees Pharmaceutical Holdings Limited - Drug Profiles 19Acetylcarnitine 19Product Description 19Mechanism of Action 19R&D Progress 19Declotana 20Product Description 20Mechanism of Action 20R&D Progress 20istaroxime 21Product Description 21Mechanism of Action 21R&D Progress 21JX-594 23Product Description 23Mechanism of Action 23R&D Progress 23levocarnitine propionate hydrochloride 25Product Description 25Mechanism of Action 25R&D Progress 25NOV-205 26Product Description 26Mechanism of Action 26R&D Progress 26
  • 3. paroxetine hydrochloride 27Product Description 27Mechanism of Action 27R&D Progress 27procarbazine hydrochloride 28Product Description 28Mechanism of Action 28R&D Progress 28prulifloxacin 29Product Description 29Mechanism of Action 29R&D Progress 29RGN-137 31Product Description 31Mechanism of Action 31R&D Progress 31RGN-259 32Product Description 32Mechanism of Action 32R&D Progress 32RGN-352 34Product Description 34Mechanism of Action 34R&D Progress 34rostafuroxin 36Product Description 36Mechanism of Action 36R&D Progress 36treprostinil 38Product Description 38Mechanism of Action 38R&D Progress 38ZK-002 39Product Description 39Mechanism of Action 41R&D Progress 41ZK-006 42Product Description 42Mechanism of Action 42R&D Progress 42ZK-008 43Product Description 43Mechanism of Action 43R&D Progress 43ZK007 44Product Description 44Mechanism of Action 44R&D Progress 44Lees Pharmaceutical Holdings Limited - Pipeline Analysis 45Lees Pharmaceutical Holdings Limited - Pipeline Products by Therapeutic Class 45Lees Pharmaceutical Holdings Limited - Pipeline Products by Route of Administration 46Lees Pharmaceutical Holdings Limited - Pipeline Products By Mechanism of Action 47
  • 4. Lees Pharmaceutical Holdings Limited - Recent Pipeline Updates 48Lees Pharmaceutical Holdings Limited - Dormant Projects 53Lees Pharmaceutical Holdings Limited - Locations And Subsidiaries 54Head Office 54Lees Pharmaceutical Holdings Limited, Recent Developments 55Lees Pharmaceutical Holdings Limited- Press Release 55Jul 31, 2012: Lees Pharma Enrolls First Patient In Phase Ib/IIa Clinical Study Of Anfibatide To Treat AcuteCoronary Syndrome 55Jun 28, 2012: Lees Pharma Completes Phase III Clinical Study Of L-Carnitine In Chronic Heart FailurePatients 56Financial Deals Landscape 57Lees Pharmaceutical Holdings Limited, Deals Summary 57Lees Pharmaceutical Holdings Limited, Pharmaceuticals & Healthcare, Deal Details 59Asset Transactions 59Powder Pharma And Lees Pharma Acquire Rights & Related Assets Of Zingo From Anesiva 59Partnerships 61Lees Pharma Enters Into Distribution Agreement With CID 61United Therapeutics Enters Into Distribution Agreement With Lees Pharma 63Leepharm Enters Into Co-Marketing Agreement With Italfarmaco 65Lees Pharma Holdings Enters Into Distribution Agreement With Helsinn 66Lees Pharma Enters Into Distribution Agreement With Italfarmaco 67Lees Pharma Enters Into Distribution Agreement With APOGEPHA 68Licensing Agreements 69RegeneRx Biopharma Enters Into Licensing Agreement With Lees Pharma For RGN-259, RGN-352 AndRGN-137 69PLx Pharma Enters Into Licensing Agreement With Lees Pharma For Cardiovascular Product 72Recordati Enters Into Licensing Agreement With Lees Pharma 73Jennerex Enters Into Collaboration And License Agreement With Lees Pharma Holdings 74Nippon Shinyaku Enters Into Licensing Agreement With Lees Pharma Holding 75Anesiva Enters Into An Agreement With Lees Pharma 76Novelos Therapeutics Enters Into Licensing Agreement With Lees Pharma 77Appendix 79Methodology 79Coverage 79Secondary Research 79Primary Research 79Expert Panel Validation 79Contact Us 80Disclaimer 80For more details contact Mr. Priyank Tiwari: sales@rnrmarketresearch.com / +18883915441Website: http://www.rnrmarketresearch.com/